Pulmatrix (NASDAQ: PULM) is developing innovative inhaled therapies to address serious pulmonary diseases, including COPD, fungal infections for Cystic Fibrosis patients, and idiopathic pulmonary fibrosis.

Joined 7/2015

3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

Introducing Litepaper, a newsletter by Stocktwits. Your lens into the world of crypto.
Join the conversation.This is where all the magic happens.